Logan energy (OTC:LOECF) Stock, Quote.Headers.trade-ideas

Logan energy Corp is a growth-oriented exploration, development and production company. It is founded with initial capitalization and three high-quality and opportunity-rich Montney assets located in the Simonette and Pouce Coupe areas of northwest Alberta and the Flatrock area of northeastern British Columbia. The company carries on the exploration,development and production of oil and natural gas.

Logan energy Corp

AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed to target both orexin-1 (OX1R) and orexin-2 (OX2R) receptors while concurrently inhibiting cathepsins. Cathepsins play significant roles in a variety of physiological processes and may offer a novel therapeutic approach for narcolepsy and other neurological disorders.

Biotech

News

Health Care

General

NLSP

NLS Pharmaceutics Says Preclinical Data Demonstrate The Potential Of Its Dual Orexin Receptor Agonist Platform, An Investigational New Drug Application Is Planned For 2026-2027

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/63b4193ec6cb260001d7903e/paul-zimbardo">Jefferies analyst Paul Zimbardo</a> initiated coverage on Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) with an Underperform rating and announced a price target of $52. Eversource Energy shares closed at $63.67 on Monday. <a href="https://www.benzinga.com/quote/ES/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein analyst Alexia Howard initiated coverage on Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) with a Market Perform rating and announced a price target of $85. Lamb Weston shares closed at $78.34 on Monday. <a href="https://www.benzinga.com/quote/lw/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley analyst Angel Castillo initiated coverage on AGCO Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with an Equal-Weight rating and announced a price target of $101. AGCO shares closed at $101.50 on Monday. <a href="https://www.benzinga.com/quote/AGCO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein analyst Nadine Sarwat initiated coverage on Coca-Cola Europacific Partners PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCEP#NASDAQ">CCEP</a>) with a Market Perform rating and announced a price target of $82. Coca-Cola Europacific shares closed at $76.40 on Monday. <a href="https://www.benzinga.com/quote/CCEP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Lee Horowitz initiated coverage on Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Hold rating and announced a price target of $37. Maplebear shares closed at $43.51 on Monday. <a href="https://www.benzinga.com/quote/CART/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ES stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03074110/image-19-1024x586.png" alt="" class="wp-image-674313" style="width:624px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03074110/image-19-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03074110/image-19-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03074110/image-19-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03074110/image-19.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42282639/honeywell-salesforce-and-3-stocks-to-watch-heading-into-tuesday">Honeywell, Salesforce And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AGCO

CART

Coca-Cola European Partners plc Ordinary Shares

CCEP

This Eversource Energy Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday

A Delaware judge once again struck down a compensation plan for Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk from 2018 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42279851/elon-musk-56b-pay-package-rejected-by-judge-again-tesla-analyst-says-a-soap-opera-playing-out-in-delaware">on Monday</a>, six months after Tesla shareholders approved the $56 billion pay package for <a href="https://www.benzinga.com/news/24/06/39323339/tesla-shareholders-approve-elon-musk-56b-pay-package-other-company-proposals" target="_blank" rel="noreferrer noopener">a second time.</a>
The Timeline: Delaware Chancery Court Judge&nbsp;Kathaleen McCormick&nbsp;ruled in January that the pay package would be voided due to Tesla&#8217;s board being influenced by Musk when they adopted the plan.&nbsp;Tesla shareholders voted again to reinstate the package in June. 
However, McCormick again ruled against the package on Monday. Tesla said in a post on X that the company deems the ruling to be wrong and intends to appeal to the Delaware Supreme Court while adding that the judge overruled a supermajority of shareholders. However, appealing could typically take around a year. 
What Next: Tesla board chair Robyn Denholm said in June prior to shareholders voting for the pay package yet again that there are multiple possibilities if the package gets rejected. The board then considered creating a new pay plan but the decision would cost shareholders more or result in decreased motivation for the company CEO, Denholm then said, as <a href="https://www.businessinsider.com/tesla-robyn-denholm-what-happens-elon-musk-pay-plan-rejected-2024-6">reported</a> by Business Insider.
Ratifying a new plan could cost the EV giant&#8217;s shareholders an additional $25 billion in the form of stock-based compensation, according to Denholm.
The 2018 pay package awarded Musk stock options if the company hit certain performance and financial targets. Musk cleared all targets, giving the award a hefty value. While the package was originally valued at up to $56 billion, it is now worth over $100 billion given the stock&#8217;s recent rally following Trump&#8217;s re-election to the white house, as per Reuters. 
According to Tesla, formulating a new pay package or offering Musk the old one could both be costly. While a settlement is possible in the lawsuit, it is unlikely given Musk&#8217;s previous track record of taking cases to trial. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42259569/chinese-ev-behemoth-and-tesla-rival-byd-marks-68-growth-in-november-sales-on-rising-popularity-of-plug-in-hybrid-evs" target="_blank" rel="noreferrer noopener">Tesla Rival BYD Marks 68% Growth In November Sales Driven By Popularity Of Plug-In Hybrid EVs</a></li>
</ul>
Photo courtesy: Shutterstock

Legal

Tech

TSLA

Tesla Chair Estimates New Pay Plan For Elon Musk Could Cost $25B More. Now, Delaware Judge Has Rejected It For The 2nd Time: Here's What's Coming Next

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) with a Market Perform and raises the price target from $121 to $138.

Price Target

Keefe, Bruyette & Woods Maintains Market Perform on Morgan Stanley, Raises Price Target to $138

PCRX

Pacira Biosciences Received U.S. Patent No. 12,156,940 From The U.S. Patent And Trademark Office, Which Protects The Chemical Composition Of Exparel (Bupivacaine Liposome Injectable Suspension). The Company Expects The '940 Patent To Provide Protection Into July 2044

Pacira Secures New U.S. Patent For EXPAREL Composition, Expanding IP Protection Through 2044

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) with a Buy and maintains $7.25 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Endeavour Silver, Maintains $7.25 Price Target

WIIM

Core & Main shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

The reverse split was approved by the Company's shareholders on November 25, 2024 and will be effective as of the commencement of trading on December 5, 2024. The reverse stock split is being implemented for the purpose of complying with the closing bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

AGRI

AgriFORCE To Implement 100-For-1 Reverse Stock Split For Nasdaq Compliance

The study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improvements in oral glucose homeostasis, and the reversal of insulin resistance to near pre-diabetic levels. These findings were supported by significantly improved Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values, a standard measure used to assess insulin sensitivity and resistance.

TELO

Telomir Pharmaceuticals Announced Preclinical Results Confirming The Efficacy Of Its Licensed Molecule Telomir-1 In Reversing Several Key Parameters Of Type 2 Diabetes Mellitus

<ul>
<li>In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle</li>
</ul>

ARWR

Arrowhead Pharmaceuticals Has Filed A Request For Regulatory Clearance To Initiate A Phase 1/2a Trial Of ARO-ALK7 As A Potential Treatment For Obesity

Keefe, Bruyette &amp; Woods analyst David Konrad maintains JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Market Perform and raises the price target from $216 to $254.

Keefe, Bruyette & Woods Maintains Market Perform on JPMorgan Chase, Raises Price Target to $254

Buybacks

Cheer Holding Approves $50M Share Buyback Program Over the Next Three Years

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>) with a Buy and maintains $15 price target.

BCTX

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $15 Price Target

On Tuesday, Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) announced that it has achieved breakthroughs in catalyzing graphitization to produce high-quality synthetic graphite with its patented green graphite production technology.&nbsp;&nbsp;
The company said its green graphite technology is the first in the world to produce artificial graphite directly from palm kernel shells, a widely available waste product in Malaysia and Indonesia.
Pilot-scale testing has demonstrated that Graphjet&#8217;s artificial graphite can achieve up to 99.99% purity levels.&nbsp;&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/12/42265847/biden-targets-china-with-new-chip-restrictions-nvidia-slides" rel="noreferrer noopener">Biden Targets China With New Chip Restrictions, Nvidia Slides</a>
In addition to the high purity levels achieved, Graphjet&#8217;s production technology boasts a 98.8% graphitization level.
The artificial graphite production process generally involves raw material mixing, molding, high-temperature and high-pressure graphitization, and modification of graphite characteristics.
A high graphitization level is key for the company&#8217;s green graphite technology. High graphitization demonstrates that the composition of the graphite lattice is highly organized and of a uniform crystal structure, which results in improved physical and chemical characteristics.
The company said graphite of this quality is a remarkable material for industries and applications such as lithium-ion batteries, thermal management, and graphite electrodes.&nbsp;&nbsp;
Third-party labs in China have validated the company&#8217;s technological achievements, the company said.
Higher graphitization levels signify a higher percentage of graphite crystal formation within a graphite sample. The graphitization level will depend on critical factors such as temperature, pressure, time, and graphitization gas.&nbsp;&nbsp;
Artificial graphite with favorable heat conductivity, stability, and chemical properties can be used to produce lithium-ion batteries, graphite electrodes, heat management, and high-performance porcelain industries.
The company said that Graphjet&#8217;s high-performance artificial graphite will enable the market to foster breakthrough technologies and new applications, thereby extending the range of applications.&nbsp;&nbsp;
Graphjet recently commissioned the world&#8217;s first and largest green graphite facility in Malaysia. The facility has an annual production capacity of up to 3,000 metric tons of battery-grade graphite. This production level supports battery production for approximately 40,000 electric vehicles annually.
The company said that per kg of graphite produced, Graphjet&#8217;s patented technology produces only 2.95 kg of CO2 emissions, compared to 16.8 kg and 17 kg from natural and synthetic graphite production in China.
Price Action: GTI stock closed lower by 6.69% at $2.51 on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42265010/amazon-and-walmart-dominate-black-friday-as-online-sales-soar-146" target="_blank" rel="noreferrer noopener">Amazon And Walmart Dominate Black Friday As Online Sales Soar 14.6%</a></li>
</ul>

Commodities

Market-Moving Exclusives

Exclusives

EXCLUSIVE: Graphjet Technology Pilot Testing Accomplishes 99.99% Graphite Purity And 98.8% Graphitization

Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), a leading beverage alcohol company, today announced that it has reached an agreement with global spirits company Sazerac, to divest its SVEDKA brand. This transaction is expected to close in the coming months.
The decision builds on the company's strategic efforts to further align the wine and spirits portfolio with evolving consumer preferences and growing market sectors, focusing on higher end wine and spirits brands and products. Over the last few years, Constellation has divested the majority of its popular and mainstream wine and spirits brands within the portfolio and is focused on competing predominantly in premium and fine wine and craft spirits segments.

Constellation Brands To Divest SVEDKA, Strengthens Focus On Premium Wine And Craft Spirits

EXCLUSIVE: Graphjet Tells Benzinga 'Achieved 99.99% graphite purity and 98.8% graphitization, two key milestones further validating the quality of Graphjet Technology's technology and its viability at scale'

EXCLUSIVE: Graphjet Tells Benzinga Co. Achieves Technological Breakthroughs With Green Graphite Production

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Bristol-Myers Squibb Company &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.00%</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $55 to $60 on Nov. 12. This analyst has an accuracy rate of 72%.</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $73 on Nov. 12. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: Bristol-Myers Squibb filed a lawsuit last week against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging that HRSA&#8217;s rejection of its proposed rebate model for the 340B Drug Pricing Program violates federal law.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">latest BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15.png" alt="" class="wp-image-674099" style="width:737px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15-768x713.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>Dividend Yield: 3.61%</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $206 on Nov. 22. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Geoff Meacham maintained a Buy rating and cut the price target from $226 to $215 on Nov. 12. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 18, AbbVie secured European Commission approval for ELAHERE, first novel therapy for platinum-resistant ovarian cancer.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"> latest ABBV new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16.png" alt="" class="wp-image-674101" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16-768x708.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)</h3>
<ul>
<li>Dividend Yield: 4.75%</li>
<li>Baird analyst Jeff Johnson maintained a Neutral rating and cut the price target from $30 to $28 on Aug. 29. This analyst has an accuracy rate of 80%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and lowered the price target from $35 to $28 on June 20. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Patterson Companies will hold its fiscal 2025 second-quarter conference call on Thursday, Dec. 5.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">PDCO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17.png" alt="" class="wp-image-674102" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17-768x705.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42267284/this-analyst-with-85-accuracy-rate-sees-more-than-8-upside-in-crowdstrike-here-are-5-stock-picks-for-november-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees More Than 8% Upside In CrowdStrike &#8211; Here Are 5 Stock Picks For November From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

ABBV

PDCO

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) with a Outperform and raises the price target from $570 to $686.

Keefe, Bruyette & Woods Maintains Outperform on Goldman Sachs Gr, Raises Price Target to $686

Logan Energ GAAP EPS of C$0.00, revenue of C$24.43M

Logan Energy GAAP EPS of C$0.00, revenue of C$24.43M

Logan Energy: Startup Year Progress

Logan Energy GAAP EPS of C$0.00, revenue of C$26.54M; reaffirms FY24 outlook

Logan Energy Production Guided To More Than 10,000 BOED As Earnings Turn Positive

The New Spartan Delta Corp.

Logan Energy: Growth Accelerates With Another Stock Offering

Logan Energy Management Has Another C$20 Million To Spend

Logan Energy GAAP EPS of C$0.01

Logan Energy upsizes equity offering to $45M

DALXF

LOECF

Logan energy

Comments

Logan energy

Logan energy (LOECF) Forecast

Logan energy (OTC:LOECF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga